A new study found a 31% increased risk of hospitalization and mortality in patients with breathing and sleep disorders. sleepassociated with hypoxia.
The research results are published in the journal “JAMA Network Open”.
The research team, led by MD Rina Mehra, analyzed retrospective data from 5,400 patients at the Cleveland Clinic.
The data obtained showed that while patients with breathing disorders during sleep and sleepthose associated with hypoxia do not have an increased risk of developing COVID-19, they have a worse clinical prognosis for the disease.
“As the COVID-19 pandemic continues and disease remains highly variable from patient to patient, it is critical to improve our ability to predict who will have more severe disease so that we can properly allocate resources,” said Dr Mehra, Research Director Sleep Disorders at the Cleveland Clinic.
“This study has improved our understanding of the link between sleep disturbances and the risk of adverse outcomes from COVID-19. It suggests that biomarkers of inflammation may mediate this relationship, ”said Dr. Mehra.
The researchers used the Cleveland Clinic’s COVID-19 Research Register, which includes data from nearly 360,000 patients tested for COVID-19 at the Cleveland Clinic, of which 5,400 had a sleep study record available.
Sleep study results and COVID-19 positivity were assessed along with disease severity. The team also took into account comorbidities such as obesity, heart and lung disease, cancer and smoking.
The findings provide the basis for additional research to determine whether early effective treatment, such as PAP (positive airway pressure) or oxygen administration, can improve COVID-19 outcomes.
“Our findings are important because reducing hospitalizations and deaths can reduce the burden on health systems,” said study first author Cynthia Pena Orbea, MD, of the Cleveland Clinic’s Sleep Disorders Center.
“If sleep-related hypoxia does lead to worse COVID-19 outcomes, risk stratification strategies should be applied to prioritize early COVID-19 therapy for this subset of patients,” Orbea added.
The study was funded by the Resource Development Award for Transformational Research in Neuroscience, which was awarded to Dr. Mehra.
This story was published from the news agency tape without text changes. Only the title has changed.